Ochaion et al. [40] reported that A3AR agonist (1′S,2′R,3′S,4′R,5′S)-4-(2-chloro-6-(3-chlorobenzylamino)-9H-purin-9-yl)-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide (CF502, MRS3558), via de-regulation of the NF-kB signaling pathway, inhibits fibroblast-like synoviocyte (FLS) growth and the inflammatory manifestations of arthritis, supporting the development of A3AR agonists for the treatment of rheumatoid arthritis. This evidence concerns the gene NFKB1 and rheumatoid arthritis.